Part Ⅰ:Biomarkers Of Acute And Chronic Kidney Disease
Mar 06, 2022
Contact: emily.li@wecistanche.com
William R. Zhang1, Chirag R. Parikh
Abstract: The current unidimensional paradigm of kidney disease detection is incompatible with the complexity and heterogeneity of renal pathology. The diagnosis of kidney disease has largely focused on glomerular filtration, while assessment of kidney tubular health has notably been absent. Following insult, the kidney tubular cells undergo a cascade of cellular responses that result in the production and accumulation of low-molecular-weight proteins in the urine and systemic circulation. Modern advancements in molecular analysis and proteomics have allowed the identification and quantification of these proteins as biomarkers for assessing and characterizing kidney diseases. In this review, we highlight promising biomarkers of kidney tubular health that have strong underpinnings in the pathophysiology of kidney disease. These biomarkers have been applied to various specific clinical settings from the spectrum of acute to chronic kidney diseases demonstrate the potential to improve patient care.
Keywords: biomarkers; acute kidney injury; AKI; chronic kidney disease; CKD; kidney
INTRODUCTION
Kidney diseases are complex and heterogeneous. Yet, clinical assessment of kidney disease largely relies largely on the glomerulus, the specialized filtering unit of the kidney. This unidimensional paradigm limits diagnosis and treatment of kidney diseases, the consequences of which are readily apparent: Both acute and chronic kidney diseases continue to outpace clinical management and are increasingly recognized as significant global health problems (1). And because these conditions are detected too late in the disease course, there have been no effective treatments developed to minimize kidney injury, alter the course of the disease, or limit the associated morbidity and mortality.
Specifically, the diagnosis of kidney disease has relied on the serum creatinine, a breakdown product of creatine and phosphocreatine, that is largely freely filtered by the glomerulus. Accessible and affordable, serum creatinine has remained the gold standard for almost a century, despite its many well-recognized limitations as an indirect marker of kidney damage, including delayed detection of injury (Table 1) (2, 3). In addition, serum creatinine can increase in the absence of glomerular or tubular injury and can be unchanged under conditions of significant tubular injury, particularly when patients have good underlying kidney function and significant kidney reserve (4–6).
To address these limitations, research employing novel technologies has focused on identifying structural markers of kidney tubular injury in the urine or systemic circulation that are directly produced by the kidney or build up as a result of the dysfunction of tubular cells following kidney damage (7–10). Linked to the pathophysiology of kidney injury, these biomarkers of tubular health may enable early detection, identification of the location of the injury, etiologic discernment, and prognostic prediction of kidney diseases. In fact, the characterization of kidney tubules may be particularly important. The vast majority of the kidney’s energy expenditure is dedicated to the homeostatic maintenance of non-glomerular functions of the kidney, and recent studies have demonstrated that prognosis of kidney disease even if glomerular in origin (11) is dependent on the extent of tubulointerstitial fibrosis. In this review, we highlight promising kidney biomarkers that have strong underpinnings in the pathophysiology of kidney injury (12). These biomarkers have been investigated in various etiologies of acute kidney injury (AKI) and have more recently extended into various presentations of chronic kidney disease (CKD). We present the results of the applications of such biomarkers in various specific clinical settings from the spectrum of acute to chronic kidney diseases, demonstrating the breadth of clinical applications of these biomarkers.

Acute and chronic kidney disease is a major global health problem
BIOMARKERS OF KIDNEY TUBULAR HEALTH
Much of the research in the field of kidney biomarkers started with investigations of AKI, a condition in which serum creatinine may not be in steady-state; thus, biomarkers that are closely correlated with true kidney tissue injury, akin to troponin for cardiac tissue, would be especially important for the detection of acute insults to the kidney. A variety of biomarkers of kidney tubular health have been identified in animal models and clinical studies that can localize to specific portions of the nephron and represent distinct mechanistic responses in the process of kidney injury. As direct indicators of kidney pathology, these biomarkers may address the limitations of serum creatinine. Several well-studied kidney biomarkers are presented with a broad physiologic overview, categorized by localization and mechanism of injury (Figures 1 and 2). These biomarkers provide a lens into the complexity of the pathogenesis of kidney injury and the heterogeneity that is not adequately captured by current approaches to characterize and treat kidney disease.
Biomarkers of Tubular Injury
As a response to the initial injury, tubular epithelial cells undergo subtle changes and release specific proteins into the urine and systemic circulation. Neutrophil gelatinase-associated lipocalin (NGAL), also known as lipocalin 2 (LCN2), is a glycoprotein bound to matrix metalloproteinase-9 in human neutrophils and is one of the most widely studied kidney biomarkers. It is a 25-kDa protein belonging to the lipocalin superfamily, which is involved in the transport of hydrophilic substances through membranes to maintain cellular homeostasis (13). Through binding bacterial siderophores and sequestering iron, NGAL inhibits bacterial growth and is important in host defense against pathogens that require iron acquisition for survival. NGAL is expressed in various tissues in the body, such as the lung, gastrointestinal tract, liver, and kidney (14), and is markedly induced in injured epithelial cells in response to injury, inflammation, and neoplastic transformation (14). Thus, while both plasma and urinary NGAL have been investigated as promising biomarkers of kidney injury, urinary NGAL is more specific to that produced by the kidney following insult. Transcriptome profiling studies in rodent models identified NGAL as one of the most upregulated genes in the kidney very early after tubular injury, particularly in distal nephron segments, and evidence suggests that it may be the earliest known marker of kidney injury (15, 16). Urinary NGAL levels were significantly elevated within 2 h of renal ischemia-reperfusion injury in mouse models (17), and both urine and serum levels were elevated within 2 h following cardiac surgery in children who developed postoperative AKI (18). In addition, in CKD, urinary NGAL levels in humans have been demonstrated to be inversely correlated with estimated glomerular filtration rate (eGFR) and directly correlated with both interstitial fibrosis and tubular atrophy (19). Based on these promising findings, commercial NGAL tests have been approved for use in the detection of AKI in Europe and Asia with pending approval by the US Food and Drug Administration (FDA).
Kidney injury molecule-1 (KIM-1), also known as T cell immunoglobulin and mucin domain-containing protein-1 (TIM-1) and hepatitis A virus cellular receptor 1 (HAVCR-1), is a 90-kDa type 1 transmembrane glycoprotein that is significantly expressed in kidneys, specifically in proximal tubular cells, following ischemic injury, whereas it is virtually absent or present at low levels in healthy kidneys (20, 21). KIM-1 has evolved as a marker of proximal tubular injury, the hallmark of virtually all proteinuric, toxic, and ischemic renal diseases. KIM-1 has been shown to be a highly sensitive and specific marker of kidney injury in several animal models of kidney disease, including models of injury due to ischemia (20, 22) and various nephrotoxins (23–28). In addition to serving as a marker of tubular injury, preclinical data have also demonstrated that KIM-1 is upregulated in the later phases of AKI and is believed to play an important role in renal repair (29).
Tissue inhibitors of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP-7) are mediators of cell-cycle arrest, a commonly induced response to kidney injury. Both IGFBP-7 (through p523 and p21) and TIMP-2 (through p27) block the effect of cyclin-dependent protein kinase complexes and cause short periods of G1 cell-cycle arrest (30–32). These biomarkers were originally discovered in the clinical setting of critical illness and have been approved by the FDA for use in conjunction with clinical evaluation in intensive care unit patients who have acute cardiovascular and/or respiratory compromise (33).

There is no effective treatment to minimize kidney injury
Biomarkers of Tubular Function
The predominant function of the adenosine 5’ -triphosphate (ATP)-rich proximal tubules is to reabsorb the majority of the filtrate. Thus, small molecules that are filtered by the glomerulus and processed or reabsorbed by the proximal tubules may serve as effective biomarkers of proximal tubular function. Increasing levels of these proteins in the urine may indicate reduced absorption by megalin, a multiligand endocytic receptor, in the proximal tubules prior to irreversible cell death. For example, cystatin C is a low-molecular-weight protein of 13 kDa produced at a constant rate by all nucleated cells and eliminated exclusively by glomerular filtration. Although it is neither secreted nor reabsorbed by renal tubules, it undergoes almost complete catabolism by proximal tubular cells and, thus, little if any appears in the urine under normal circumstances. Impairment of reabsorption in the proximal tubules can lead to marked increases in urinary levels of cystatin C in animals and humans (34, 35).
α1-Microglobulin (α1M) is another prototypical example of a marker of proximal tubular function. α1M is a low-molecular-weight glycoprotein of approximately 27 to 30 kDa and another member of the lipocalin superfamily. α1M is primarily synthesized by the liver and is available both in free form and as a complex with immunoglobulin A (IgA) (36). α1M is freely filtered at the glomerulus and completely reabsorbed via megalin mediation and catabolized by the normal proximal tubule. Therefore, an increase in the urinary concentration of α1M indicates proximal tubular injury or dysfunction, and patients with renal tubular diseases have been found to have elevated urinary α1M levels. Unlike β2- microglobulin and retinol-binding protein, which follow an analogous mechanism, α1M is more stable over a range of pH levels in the urine (37), which has currently made it a superior urinary biomarker of tubular dysfunction.
L-type or lever-type fatty acid-binding protein (L-FABP) is a 15-kDa protein that selectively binds to free fatty acids and transports them to mitochondria or peroxisomes, where free fatty acids are β-oxidized and participate in intracellular fatty acid homeostasis. First isolated in the liver as a binding protein for oleic acid and bilirubin, there are now known to be several different types of FABPs, which are expressed in a variety of tissues. Circulating L-FABP is thought to be filtered at the glomeruli and reabsorbed by proximal tubular cells. Although it is not synthesized in mouse models, L-FABP is expressed in the proximal tubules of humans following acute ischemic injury (38). Accordingly, elevated L-FABP levels have been shown to be a sensitive and specific marker of AKI in both adults and children (39, 40). Because L-FABP is also expressed by the liver, liver injury can be a potential contributor to increased urinary levels of this biomarker during AKI. However, previous clinical studies have shown that serum L-FABP levels do not have a significant influence on urinary levels and that urinary L-FABP levels are not significantly higher in patients with liver disease than in healthy subjects (39–42).
Uromodulin (UMOD), also known as Tamm-Horsfall protein, is an 85-kDa glycoprotein exclusively produced by cells of the thick ascending limb of Henle. It is the most abundant protein in physiologic urine and, with a large number of cysteine residues, has a tendency to aggregate and is the major constituent of hyaline casts (43). While UMOD’s physiologic function has yet to be elucidated, it has been implicated in the regulation of salt homeostasis and conferring immunologic renal protection, including preventing infections and inhibiting nephrolithiasis. Studies in animal models and clinical settings have demonstrated its ability to serve as a biomarker for tubular mass and function and, accordingly, UMOD has been shown to be inversely associated with many kidney disease states. Evidence also shows that UMOD is a direct marker of the amount of intact tubular cells of the ascending limb of the loop of Henle and thus may represent a marker for the number of remaining functional tubules (44).

Kidney biomarkers are important for detecting kidney injury
Biomarkers of Kidney Inflammation
The activation of inflammatory pathways within the kidneys and recruitment of inflammatory cells to the site of injury is early response to kidney injury; such inflammatory mediators include interleukin-18 (IL-18), an 18-kDa proinflammatory cytokine, and a member of the IL-1 superfamily. As an early response to injury, the precursor of this inflammatory cytokine, pro-IL-18, is cleaved by caspase 1 within renal tubule cells and macrophages, and IL-18 is released into the tubular lumen and systemic circulation. Preclinical studies have demonstrated that IL-18 is a mediator of acute tubular injury, inducing both neutrophil and monocyte infiltration of the renal parenchyma (45, 46). In addition, IL-18 has been demonstrated to play a major role in macrophage activation, with mice engrafted with IL-18-deficient bone marrow experiencing less AKI than those with IL-18 replete marrow (47). Similarly, in IL-18 knockout mice with AKI, tumor necrosis factor-α (TNF-α), inducible nitric oxide synthase, macrophage inflammatory protein-2, and monocyte chemoattractant protein-1 (MCP-1) messenger RNA expression are all decreased, demonstrating the key inflammatory mediating effects of IL-18 on AKI. The immune response involves a variety of additional mediators, including IL-6 and IL-10. IL-6 is a major pro-inflammatory mediator that is well characterized in the orchestration of the inflammatory response following acute renal insult and has been shown to be a superior marker in renal patients compared with other proinflammatory candidates, such as the systemic inflammatory marker C-reactive protein. On the other hand, IL-10 is a prototypical anti-inflammatory cytokine that carries out the critical function of modulating and suppressing inflammation, antagonistic to the effects of IL-6.
In addition, kidney tubular cells also produce MCP-1 in response to proinflammatory cytokines, including TNF-α and IL-1β (48). MCP-1 is a chemotactic protein that attracts blood monocytes and tissue macrophages through interaction with the C-C motif cellsurface receptor chemokine receptor 2 (CCR2) (49, 50). In response to proinflammatory stimuli, MCP-1 is expressed in a variety of human cell types, including fibroblasts, endothelial cells, peripheral blood mononuclear cells, and epithelial cells (50–54). The lack of correlation between urinary and serum MCP-1 levels suggests that urinary MCP-1 is locally produced by the kidney rather than as a result of filtration of serum MCP-1 (55–57).
Soluble TNF receptors (TNFR1 and TNFR2), circulating markers of low-grade inflammation, have also recently been demonstrated as biomarkers of kidney disease. These soluble proteins are the circulating forms of the receptors shed from their membrane-bound counterparts, which are integral to TNF signaling pathways, and have been demonstrated to play important roles in the progression of atherosclerotic and kidney disease (58–60). Specifically, the TNF pathway has been involved in the development and progression of diabetic nephropathy in animal models (61), and TNF inhibition with the soluble TNFR2 fusion protein, etanercept, has improved albuminuria and tissue injury (62). TNF receptors belong to the TNF receptor superfamily, a group of type 1 single transmembrane glycoproteins. The binding of TNF-α to TNFRs regulates inflammatory responses and apoptosis via activation of nuclear factor kappa B (NF-κB) or activator protein 1 (AP-1). In humans, early studies have shown that increased levels of circulating TNFRs are strongly associated with the progression of diabetic nephropathy to CKD stage 3 and end-stage renal disease (ESRD), and with all-cause mortality (59, 60, 63). Although the literature has predominantly supported their use in diabetic nephropathy, subanalyses of nondiabetic patients in these studies have also confirmed their utility in other etiologies of kidney disease (64).

Early examination and treatment can increase the chance of reversing kidney injury
Biomarkers of Adaptive Repair and Fibrosis
Following inflammation, an injury may be followed by reparative processes or ongoing progression of inflammation that eventually leads to fibrosis. These tightly regulated pathways of adaptive repair and fibrosis may be captured by urinary biomarkers involved in these pathways. YKL-40, also known as chitinase 3-Dislike protein 1 and BRP-39 in mice, is a 40-kDa inflammatory glycoprotein produced in a wide range of inflammatory cell types involved in modulating favorable responses to cellular damage (65). It has been hypothesized that this protein may signal the adaptive repair response following inflammation. For example, in hypoxic lung injury, BRP-39/YKL-40 has been demonstrated to limit lung injury, inflammation, and epithelial apoptosis (66). Studies of Brp39 knockout mice have revealed that macrophage-derived BRP-39 was critical in limiting renal tubular apoptosis via activation of Akt (also known as PKB, protein kinase B), and thus improved survival following renal ischemic-reperfusion injury (67).
In contrast, other biomarkers reflect the deposition of the extracellular matrix that is the hallmark of fibrosis. Under physiologic conditions, kidneys have small amounts of collagen present in the interstitium, whereas kidneys having undergone progressive and sustained injury exhibit increased collagen production. Procollagen type III N-terminal propeptide (PIIINP) is the 42-kDa amino acid terminal peptide of type III procollagen, which is released during the synthesis and deposition of type III collagen. Urinary PIIINP levels are accordingly believed to be biomarkers of early stages of kidney fibrosis. Studies have found that urinary PIIINP levels did not correlate with proteinuria and thus likely represent an intrarenal synthesis of this peptide (68). Ongoing work has focused on the evolving understanding of the pathophysiology of kidney injury in the modulation of renal repair. In contrast to the heart and brain, the kidney possesses intrinsic regenerative abilities following ischemic and toxic insults. Whether the repair is promptly initiated or delayed may play an important role in outcomes following kidney injury. Thus, the process of and balance between adaptive and maladaptive repair may be an important junction for therapeutic intervention and has been the focus of active research efforts. Kidney biopsies are invasive and relatively difficult procedures and, thus, quantifying early fibrosis in CKD may become feasible with these noninvasive biomarkers.
For example, epidermal growth factor (EGF), which has been implicated in modulating the tubular response to injury (69, 70), was identified as a biomarker of chronic kidney disease via a renal biopsy transcriptome-driven discovery approach in a study of four diverse cohorts (71). Through an unbiased functional analysis of gene expression data, EGF was uniquely identified to be involved in kidney function decline. Along with intrarenal EGF mRNA, urinary EGF was found to be tightly correlated with eGFR at the time of biopsy and with longitudinal changes in eGFR, independent of traditional risk factors. Furthermore, EGF added predictive power to traditional clinical prognostic markers of CKD progression endpoints across the four diverse cohorts. As an especially promising biomarker, urinary EGF has been shown to be highly specific to the kidney and is normally minimally present in the plasma (72). Thus, it has been postulated that EGF may be a biomarker of the regenerative functional reserve and reflect the ability to respond to insults. Consistent with this understanding, exogenous EGF administration enhanced tubular repair and regeneration of kidney function in animal models of AKI; interestingly, however, in the presence of pro-inflammatory stimuli, EGF further exacerbated injury (73). In addition, urinary EGF has been shown to be inversely correlated with interstitial fibrosis (74), diabetic nephropathy (75), IgA nephropathy (69, 76), adult polycystic kidney disease (77), and pediatric CKD (78).

Kidney injury may cause kidney fibrosis
CLINICAL APPLICATIONS
Irrespective of etiology or clinical setting, a given loss of GFR due to kidney disease is detected by identical rises in serum creatinine levels. However, the meaning of these elevations in serum creatinine with respect to underlying mechanisms of injury and outcomes may significantly differ based on the physiologic context and the milieu in which the elevations occur. Biomarkers of tubular health have the ability to provide greater resolution into the nuances and complexities of these conditions, which have demonstrated the ability to improve detection, identify disease susceptibility, diagnose subclinical kidney disease, and predict the prognosis of adverse events in a variety of clinical settings. It has become increasingly appreciated that any single biomarker may be insufficient to characterize the disease state. Rather, these biomarkers are context-dependent. Accordingly, different biomarkers have demonstrated utility in different settings, reflecting the unique aspects of the underlying mechanisms of injury (Figure 3). Understanding the relationships between these different biomarker categories may improve the understanding of and ability to phenotype these disease processes and, in turn, inform the development of novel therapeutic compounds. We highlight observational data from several diverse clinical contexts in which these biomarkers have shown promise in advancing clinical care.

These biomarkers show promise in advancing clinical care of chronic kidney disease






